Adagio Medical to Present at Roth Conference Amid Key Clinical Trial
Event summary
- Adagio Medical will participate in the 38th Annual Roth Conference on March 23-24, 2026, hosting investor meetings.
- The company's vCLAS™ Cryoablation System is under evaluation in the FULCRUM-VT U.S. Pivotal IDE Trial with 209 enrolled patients.
- vCLAS is CE Marked and commercially available in Europe but remains investigational in the U.S.
- Results from FULCRUM-VT will support a potential FDA premarket approval (PMA) application.
The big picture
Adagio Medical's participation in the Roth Conference comes as it navigates the critical phase of its FULCRUM-VT trial, which could determine U.S. market access for its vCLAS system. The company is operating in a competitive cardiac ablation space, where regulatory approval and clinical differentiation are key to capturing market share. Success in the trial and subsequent FDA approval would position Adagio to challenge established players in the $4B+ global ablation market.
What we're watching
- Regulatory Pathway
- The pace at which FULCRUM-VT results could lead to FDA PMA approval for vCLAS in the U.S.
- Commercial Expansion
- Whether Adagio can leverage Roth Conference exposure to accelerate investor interest and funding.
- Clinical Efficacy
- How the trial outcomes will position vCLAS against competing ablation technologies.